News Release

More accurate, quicker diagnoses possible via new Elsevier product

Elsevier launches Path Consult – cutting-edge, online clinical decision support tool for pathologists

Business Announcement

Elsevier

Path Consult is designed to be used in the workplace as a differential diagnosis tool to provide clinical decision support covering every subspecialty area of general pathology. For the first time, pathologists will be able to conduct a side-by-side comparison of up to three diagnoses at a time, significantly reducing the amount of time spent researching the same information offline.

"Path Consult demonstrates Elsevier's commitment to customers by delivering a truly innovative tool for the end user. Our agile development process is designed to maximize this value in minimum time," says Jonathan Clark, Executive Vice President, Technology at Elsevier.

Using its established industry leading references from Mosby, Saunders, and Churchill Livingstone, Elsevier developed Path Consult to include more than 10,000 images for more than 500 conditions at launch, and more than 20,000 images for 1200 diagnoses by Fall of 2006.

Path Consult was developed using an agile development process that closely engaged development partners so Elsevier could quickly bring the product to market with the features pathologists really want. The agile process involves a series of product iterations which are adapted based on feedback.

Elsevier worked with leading pathologists to ensure the quality, accuracy, and usability of the online resource. "A plethora of expertly-obtained digital images and succinct textual content combined with the ability to compare similar histopathologic entities at the touch of a button will make the job of any pathologist easier," says John D. Cochran, MD, a private practice pathologist in Atlanta, Georgia who worked with Elsevier on the development of the product.

###

Group practices and institutions can sign up for a free trial by visiting www.pathCONSULTDDX.com.

About Elsevier
Elsevier is a world-leading publisher of scientific, technical and healthcare information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in 74 offices worldwide publish more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, such as MD Consult (http://www.mdconsult.com/, FIRST Consult (http://wwwFIRSTConsult.com), Mosby's Nursing Consult (http://www.mosbysnursingconsult.com, ScienceDirect (http://www.sciencedirect.com/),), Scopus (http://www.news.scopus.com/), bibliographic databases, online reference works and subject specific portals.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and healthcare, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.